United States

People: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

22 Feb 2017
Change (% chg)

8.50 (+0.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Slaoui, Moncef 

Dr. Moncef Slaoui is no longer as Chairman - Global Vaccines, Executive Director of GlaxoSmithKline PLC, effective 31 March 2017. He joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was given overall responsibility for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. Moncef has advised the US President’s Council of Advisors on Science and Technology and he was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. External appointments Moncef is a member of the Biotechnology Industry Organization Board in the US and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. Moncef serves as a Non-Executive Director for the International AIDS Vaccine Initiative (IAVI).

Basic Compensation

Total Annual Compensation, GBP 2,844,000
Restricted Stock Awards, GBP --
Long-Term Incentive Plans, GBP 2,619,000
All Other, GBP 1,861,000
Fiscal Year Total, GBP 7,324,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --